Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
7.59
-0.38 (-4.77%)
Feb 17, 2026, 10:44 AM EST - Market open
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$657,313
Market Cap
626.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | 152 | 30 | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| ProKidney | 204 |
| Kura Oncology | 192 |
| Rigel Pharmaceuticals | 164 |
| Alpha Tau Medical | 125 |
| Cullinan Therapeutics | 111 |
| enGene Holdings | 82 |
| Fulcrum Therapeutics | 45 |
REPL News
- 14 days ago - Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - The Short List — Top 10 Most Shorted Stocks Right Now - Benzinga
- 3 months ago - Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) - GlobeNewsWire
- 3 months ago - Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma - GlobeNewsWire
- 4 months ago - Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 - GlobeNewsWire